CRESCENT BIOPHARMA, INC.

Fundamental score not available. AIR's fundamental engine is built for businesses with established revenue and cash flow; biotech financial profiles — often R&D-heavy or pre-revenue — don't yet fit the measures it requires. AIR still assesses this company on discovery, market confirmation and risk, at reduced overall confidence.

This month at a glance

Evidence timeline

1. [8-K 2.02] CRESCENT BIOPHARMA, INC. — Results of Operations and Financial ConditionSEC · SEC EDGAR
   Jul 30, 2026 · 8-K
2. [8-K 8.01] CRESCENT BIOPHARMA, INC. — Other EventsSEC · SEC EDGAR
   Jul 14, 2026 · 8-K
3. [8-K 2.02] CRESCENT BIOPHARMA, INC. — Results of Operations and Financial ConditionSEC · SEC EDGAR
   Jul 14, 2026 · 8-K
4. [8-K 2.02] CRESCENT BIOPHARMA, INC. — Results of Operations and Financial ConditionSEC · SEC EDGAR
   Apr 29, 2026 · 8-K
5. [8-K 2.02] CRESCENT BIOPHARMA, INC. — Results of Operations and Financial ConditionSEC · SEC EDGAR
   Feb 26, 2026 · 8-K
6. [8-K 3.02] CRESCENT BIOPHARMA, INC. — Unregistered Sales of Equity SecuritiesSEC · SEC EDGAR
   Dec 2, 2025 · 8-K
7. [8-K 1.01] CRESCENT BIOPHARMA, INC. — Entry into a Material Definitive AgreementSEC · SEC EDGAR
   Dec 2, 2025 · 8-K
8. [8-K 8.01] CRESCENT BIOPHARMA, INC. — Other EventsSEC · SEC EDGAR
   Dec 2, 2025 · 8-K
9. [8-K 2.02] CRESCENT BIOPHARMA, INC. — Results of Operations and Financial ConditionSEC · SEC EDGAR
   Nov 6, 2025 · 8-K
10. [8-K 2.02] CRESCENT BIOPHARMA, INC. — Results of Operations and Financial ConditionSEC · SEC EDGAR
    Jul 29, 2025 · 8-K
11. [8-K 5.02] CRESCENT BIOPHARMA, INC. — Departure/Election of Directors or Principal OfficersSEC · SEC EDGAR
    Jul 29, 2025 · 8-K
12. [8-K 1.01] CRESCENT BIOPHARMA, INC. — Entry into a Material Definitive AgreementSEC · SEC EDGAR
    Jun 13, 2025 · FORM 8-K

What would change our view

Research, not tips. No buy/sell recommendations, no price forecasts. Every score is derived from public filings and market data — figures round to whole numbers and refresh each trading day.